Eisai Biogen's Leqembi Alzheimer's drug shows benefits over three years
The newly FDA-approved Alzheimer's treatment, Leqembi, will be prepared at Abington Neurological Associates in Abington, Pennsylvania on Tuesday, November 7,…
Biotechnology and pharmaceuticals
Novo Nordisk's liraglutide GLP-1 may slow the progression of Alzheimer's
A box of the drug Victoza, manufactured by Novo Nordisk Pharmaceutical, sits on a pharmacy counter in Provo, Utah, January…
Pfizer (PFE) Q2 2024 Results
Kena Betancur | Corbis News | Getty Images Pfizer on Tuesday reported second-quarter revenue and adjusted earnings that beat expectations…
Merck (MRK) Q2 2024 Results
An exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on February 5, 2024. Spencer Platt |…
FDA approves new blood test to detect colon cancer
The Food and Drug Administration approved on Monday 'Guardian Health'The blood test, called Shield, is used to detect colon cancer.…
These drugmakers are catching up to Eli Lilly and Novo Nordisk
The lucrative market for weight-loss drugs won’t be a duopoly forever. With billions at stake, that’s been a virtual guarantee…
Biogen Eisai's Leqembi Alzheimer's drug rejected by EU regulator
European drug regulators on Friday rejected Leqembi's Alzheimer's treatment Biogen and Eisaicreating another hurdle for companies as they struggle to…
Bristol Myers Squibb (BMY) Q2 2024 Results
Bristol Myers Squibb's research and development center at Cambridge Crossing in Cambridge, Massachusetts, on December 27, 2023. Adam Glanzman |…
Fund manager of names in weight loss and biotechnology
Weight-loss drugs have sparked investor interest and shaken up other sectors over the past year. Novo Nordisk and Eli Lilly…
Viking Therapeutics shares rise on plans to test weight-loss injection
Weight loss drug concept. Cr | Istock | Getty Images Actions of Viking Therapeutics rose more than 20% on Thursday…